Evidence map›Paper›PMID 29789395›Full record

ArticleStroke2018

Blood Pressure-Attained Analysis of ATACH 2 Trial.

Adnan I Qureshi, Yuko Y Palesch, Lydia D Foster, William G Barsan, Joshua N Goldstein, Daniel F Hanley, Chung Y Hsu, Claudia S Moy, Mushtaq H Qureshi, Robert Silbergleit and 4 more

2 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stroke, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01176565 phase3terminatednot on this map

Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH)-II: A Phase III Randomized Multicenter Clinical Trial of Blood Pressure Reduction for Hypertension in Acute Intracerebral Hemorrhage

TypeinterventionalSponsorUniversity of MinnesotaRan2011 to 2016Enrolled1,000ConditionsIntracerebral HemorrhageArmsIntravenous nicardipine hydrochloride
NCT04167644 completednot on this map

Proper Timing of Control of Hypertension and Outcome in Acute Spontaneous Intracerebral Hemorrhage.

TypeobservationalSponsorMansoura University HospitalRan2018 to 2019Enrolled150ConditionsIntra Cerebral Hemorrhage, HypertensionArmsModified Rankin Scale (mRS)
3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Hypertensive Emergency Team-Based Learning.Journal of education & teaching in emergency medicine · 2024
    Article
  5. Review
  6. Article
  7. Article
  8. Observational
  9. Review
  10. Advances in Therapeutic Approaches for Spontaneous Intracerebral Hemorrhage.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020
    Review
  11. [Acute treatment of intracerebral hemorrhage].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2019
    Review
  12. Impact of Recent Studies for the Treatment of Intracerebral Hemorrhage.Current neurology and neuroscience reports · 2018
    Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Adnan I QureshiFrom the Department of Neurology, Zeenat Qureshi Stroke Research Center, University of Minnesota, Minneapolis (A.I.Q., M.H.Q.) qureshai@gmail.com.
Yuko Y PaleschDepartment of Public Health Sciences, Medical University of South Carolina, Charleston (Y.Y.P., L.D.F.).
Lydia D FosterDepartment of Public Health Sciences, Medical University of South Carolina, Charleston (Y.Y.P., L.D.F.).
William G BarsanDepartment of Emergency Medicine, University of Michigan, Ann Arbor (W.G.B., R.S.).
Joshua N GoldsteinDepartment of Emergency Medicine, Massachusetts General Hospital, Boston (J.N.G.).
Daniel F HanleyDepartment of Neurology, Johns Hopkins University, Baltimore, MD (D.F.H.).
Chung Y HsuDepartment of Neurology, China Medical University, Taichung, Taiwan (C.Y.H.).
Claudia S MoyDivision of Clinical Research, National Institutes of Health, Bethesda, MD (C.S.M.).
Mushtaq H QureshiFrom the Department of Neurology, Zeenat Qureshi Stroke Research Center, University of Minnesota, Minneapolis (A.I.Q., M.H.Q.).
Robert SilbergleitDepartment of Emergency Medicine, University of Michigan, Ann Arbor (W.G.B., R.S.).
Jose I SuarezDepartment of Neurology, Baylor College of Medicine, Houston, TX (J.I.S.).
Kazunori ToyodaDepartment of Neurology, National Cerebral and Cardiovascular Center, Suita, Japan (K.T., H.Y.).
Haruko YamamotoDepartment of Neurology, National Cerebral and Cardiovascular Center, Suita, Japan (K.T., H.Y.).
ATACH 2 Trial Investigators

Funding

Neurologic Emergencies Treatment Trials Network: Clinical Coordinating CenterU01NS056975 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BARSAN, WILLIAM G · 2006 to 2015
$40.4M
Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH-II)U01NS062091 · NINDS · UNIVERSITY OF MINNESOTA · PI QURESHI, ADNAN IQBAL · 2010 to 2014
$18.1M
Neurological Emergencies Treatment Trials Network Statistical and Data ManagementU01NS059041 · NINDS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI DURKALSKI, VALERIE L, PALESCH, YUKO Y · 2006 to 2015
$9.1M
Statistical and Data Coordinating Center for the ATACH - 2U01NS061861 · NINDS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI PALESCH, YUKO Y · 2010 to 2014
$2.2M
NINDS NIH HHS U01 NS056975NINDS NIH HHS U01 NS059041NINDS NIH HHS U01 NS061861NINDS NIH HHS U01 NS062091
6 · The paper itself

Abstract

background and purposeWe compared the rates of death or disability, defined by modified Rankin Scale score of 4 to 6, at 3 months in patients with intracerebral hemorrhage according to post-treatment systolic blood pressure (SBP)-attained status.

methodsWe divided 1000 subjects with SBP ≥180 mm Hg who were randomized within 4.5 hours of symptom onset as follows: SBP <140 mm Hg achieved or not achieved within 2 hours; subjects in whom SBP <140 mm Hg was achieved within 2 hours were further divided: SBP <140 mm Hg for 21 to 22 hours (reduced and maintained) or SBP was ≥140 mm Hg for at least 2 hours during the period between 2 and 24 hours (reduced but not maintained).

resultsCompared with subjects without reduction of SBP <140 mm Hg within 2 hours, subjects with reduction and maintenance of SBP <140 mm Hg within 2 hours had a similar rate of death or disability (relative risk of 0.98; 95% confidence interval, 0.74-1.29). The rates of neurological deterioration within 24 hours were significantly higher in reduced and maintained group (10.4%; relative risk, 1.98; 95% confidence interval, 1.08-3.62) and in reduced but not maintained group (11.5%; relative risk, 2.08; 95% confidence interval, 1.15-3.75) compared with reference group. The rates of cardiac-related adverse events within 7 days were higher among subjects with reduction and maintenance of SBP <140 mmHg compared to subjects without reduction (11.2% versus 6.4%).

conclusionsNo decline in death or disability but higher rates of neurological deterioration and cardiac-related adverse events were observed among intracerebral hemorrhage subjects with reduction with and without maintenance of intensive SBP goals. CLINICAL

trial registrationURL: https://www.clinicaltrials.gov. Unique identifier: NCT01176565.

Indexed as

AgedAntihypertensive AgentsBlood PressureBlood Pressure DeterminationCerebral HemorrhageClinical Trials as TopicFemaleHumansHypertensionMaleMiddle AgedNicardipineTreatment OutcomeAntihypertensive AgentsNicardipineacute hypertensive responseblood pressurecerebral hemorrhageclinical trialhumans

Identifiers

PMID29789395
PMCPMC7224409

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.